Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Revenue of Aerovate Therapeutics, Inc. (AVTE)
Revenue in 2023 (TTM): $
According to Aerovate Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Aerovate Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-96,000 | $-81,313,000 | $-75,465,000 | $-75,521,000 |
| 2022 | $ | $-68,000 | $-53,169,000 | $-51,486,000 | $-51,511,000 |
| 2021 | $ | $-15,000 | $-23,007,000 | $-22,960,000 | $-22,963,000 |
| 2020 | $ | $-1,000 | $-9,535,000 | $-9,611,000 | $-9,039,000 |
| 2019 | $ | $ | $-3,330,000 | $-3,330,000 | $-3,330,000 |